Novo Nordisk A/S is testing small doses of its blockbuster Wegovy pill in a new study that will help establish how low patients can keep their dose and still lose weight.

LONDON, Aug 19 (Reuters) - Danish drugmaker Novo Nordisk is testing lower doses of its Wegovy pill in a new late-stage study to find the lowest dose that still helps patients lose weight, according to ...

Novo Nordisk (NVO) is testing lower doses of its Wegovy obesity pill in a new study aimed at determining how low patients can go in their dose while still achieving weight loss. The 450-patient trial ...

Eight months ago, Novo Nordisk introduced an oral form of semaglutide for obesity known as the ‘Weggovy pill’. Now the company is testing whether lower maintenance doses of the drug can still help ...

Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo Nordisk is testing the GLP-1 in smaller doses in the late-stage OASIS 5 study.

Novo Nordisk NOVO.B1.84%increase; up pointing triangle is studying smaller doses of its Wegovy weight-loss pill to find the lowest dose that patients can take and still lose weight, according to a U.S ...

Novo Nordisk stock is holding steady after the company raised its 2026 outlook alongside Q2 results and began a 450-patient trial to test lower doses of its Wegovy weight-loss pill. Novo Nordisk A/S ...

Novo Nordisk stock holds its recent range as the company launches a Phase 3 trial of lower maintenance doses for its oral Wegovy pill, while investors weigh second-quarter 2026 obesity-drug revenues ...

The OASIS-5 trial will recruit 450 adults with BMI 30 or above, or 27 with an obesity-related health issue.

Novo Nordisk has begun a late-stage trial testing lower doses of its oral Wegovy pill. The placebo-controlled trial, called OASIS 5, began enrolling patients Aug. 12 and will compare two undisclosed ...